<DOC>
	<DOCNO>NCT01923233</DOCNO>
	<brief_summary>This study individualize anti-cancer vaccine protocol vaccination occur inside body . To create vaccine , tumor lesion select cause die process call `` Radiofrequency Ablation '' RFA . RFA cause tumor release internal content surround environment , content include tumor-specific antigen . Immune cell respond tissue damage take-up tumor antigen . The injection experimental cell drug , AlloStim ( TM ) lesion design cause respond cell signal immune system danger tumor , create tumor-specific immunity .</brief_summary>
	<brief_title>In-Situ Therapeutic Cancer Vaccine Refractory Liver Cancer</brief_title>
	<detailed_description>The protocol design 4 step : ( 1 ) priming ; ( 2 ) vaccination , ( 3 ) activation ( 4 ) boosting . The priming step involve intradermal injection AlloStim ( TM ) . This designed increase circulate titer allo-specific Th1 memory cell ; vaccination step involve percutaneous radiofrequency ablation single liver lesion follow immediately intratumoral injection AlloStim ( TM ) ablate lesion , follow 3 day later additional intratumoral injection previously ablate lesion AlloStim ( TM ) . This step design elicit tumor-specific Th1 immunity . The activation step involve intravenous infusion AlloStim ( TM ) . This step design cause activation extravasation circulate memory cell activation innate immune cell . The booster step include two monthly IV infusion AlloStim ( TM ) . This step design maintain inflammatory cytokine storm design counteract immune suppressor mechanism tumor immunoavoidance mechanism .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>1 . Any patient diagnosis HCC base histology current accept radiological measure . 2 . Age &gt; 18 year . 3 . Patient MRI CT result ( positive HCC ) 3 month prior recruitment . 4 . AFP &gt; 30 . 5 . Patient eligible fail HCC treatment . 1 . Patient unable unwilling sign inform consent . 2 . Patients participate clinical trial evaluate experimental treatment procedures 3 . Severe congestive heart failure ( LVEF echocardiogram &lt; 20 % ) . 4 . Severe pulmonary hypertension ( By echocardiogram , PAS &gt; 45 mmHg ) . 5 . Uncontrolled diabetes mellitus ( HBA1C &gt; 9.5 % ) . 6 . Any autoimmune disorder , currently treat prednisone immune suppressive medication . 7 . Patients currently receive total parenteral nutrition contraindication oral drug . 8 . Subjects positive HIV . 9 . Women pregnant breast feeding . 10 . Patient , base opinion investigator , enrol study . 11 . HBsAg positive HBV DNA positive . 12 . If patient HBcAB positive HBsAG negative , irrespective anti HBS status , enrol receive preemptive therapy Lamivudine . 13 . Any metastasis except portal vein involvement . 14 . Subjects Child Pugh B8 . 15 . Prior experimental therapy cancer vaccine treatment ( e.g. , dendritic cell therapy , heat shock vaccine ) . 16 . History blood transfusion reaction . 17 . Known allergy bovine murine product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>liver cancer</keyword>
	<keyword>HCC</keyword>
	<keyword>tumor vaccine</keyword>
	<keyword>immunotherapy</keyword>
</DOC>